Preamble

Doping in sport relies primarily on the misuse and abuse of newly developed and commercially available medicines. Doping affects the fairness of sport competitions by illegally enhancing athletic performance and also causes potentially harmful health effects for the doped athletes. Not only is the elite athlete population affected, but also amateur and occasional athletes, as well as people aiming at improving their physical appearance. Today, doping is considered a public health issue by national authorities.

The international fight against doping in sport takes place through cooperation among multiple stakeholders. The results of several collaborations between the R&D pharmaceutical industry and anti-doping authorities have shown the mutual benefit in developing anti-doping capacity for newly developed and commercially available medicines.

Scope

Because the World Anti-Doping Agency (WADA) leads international efforts to promote, coordinate, and monitor the fight against doping in sport in all its forms; and because the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) represents the innovative pharmaceutical industry, which is committed to the development of anti-doping capacity for medicines as a further contribution to improving global public health, WADA and IFPMA have decided to develop this

JOINT DECLARATION ON COOPERATION IN THE FIGHT AGAINST DOPING IN SPORT

Objective

The aim of this declaration is to facilitate the development of voluntary working relationships between WADA and IFPMA member companies in support of the following activities:

1. Identify compounds with a potential for sport-related doping abuse and establish mechanisms to inform member companies and WADA

2. Help minimize, during clinical trials, the risk of misuse of medicines with doping potential to avoid any opportunities for abuse, e.g.
   - By informing investigators of the risks of doping abuse
- Including clauses in contractual agreements between sponsors and investigators
- Emphasizing the importance of the control of unused medicinal products

3. On a case-by-case basis, facilitate the transfer of information relevant to doping abuse under specific agreements in conformance with the Principles described below

4. Facilitate the development of detection methods in WADA-accredited laboratories or in those otherwise approved by WADA

5. Collaborate on appropriate communication plans when medicines are associated with doping cases

Principles

- Any and all information to be shared between companies and WADA is on a voluntary basis.
- Sharing of information will be determined on a case-by-case basis and only for those compounds for which in-house screening or external information indicates a likely or probable doping abuse potential.
- Protection of any proprietary or confidential information will be achieved by means of a confidentiality agreement. Information will be shared only with WADA employees and not with any third parties, unless mutually agreed in writing.
- It is preferable that a key contact person is designated in WADA and in each company to simplify and streamline general communication. All information exchanged between the company and WADA about compounds having doping potential will be conveyed via the identified contact persons.
- In case of genuine doping abuse potential of a compound, exchanges between the company and WADA will be further developed:
  - WADA will provide the list of information sought in order for it to develop an anti-doping method;
  - The company and WADA will exchange, at a frequency to be jointly agreed by the two parties, information on the drug development and on the development and implementation by WADA of the anti-doping method(s).

WADA and IFPMA will monitor jointly the implementation of this declaration through annual reviews.
This Joint Declaration has been recognized by WADA Executive Committee in May 2010 and was agreed by the IFPMA Council at its meeting on June 10, 2010, and enters force upon its signature by the Presidents of these two organizations, below:

__________________________________________  _______________________________________
Mr. David Howman                          Mr. Haruo Naito
WADA Director General                     IFPMA President